Moderna’s Bundibugyo ebolavirus vaccine candidate cleared for Phase 2/3 trial in DRC
Moderna announced that its investigational mRNA‑1469 vaccine against Bundibugyo ebolavirus has been recommended by the WHO’s technical advisory group for inclusion in a Phase 2/3 efficacy trial in the Democratic Republic of the Congo. The study, called Tumaini, will evaluate the vaccine’s ability to protect contacts of confirmed cases using a ring‑vaccination design. The recommendation follows an October 22 review of pre‑clinical data and encouraging Phase 1 results in healthy adults. Moderna will conduct the trial in partnership with CEPI, the DRC Ministry of Health and other global health partners.
Why it matters
The WHO endorsement moves the candidate toward a pivotal efficacy assessment, which could lead to regulatory approval and large‑scale deployment if successful, creating a potential new revenue stream for Moderna. The trial also positions Moderna as a key player in responding to emerging Ebola‑type outbreaks, which may attract further public‑sector funding.
Key facts
- 1The WHO Technical Advisory Group reviewed the evidence on October 22 and recommended mRNA‑1469 for the Phase 2/3 trial. stocktitan.net
- 2Moderna’s Phase 1 study in Canada showed the vaccine was generally well tolerated and generated strong BDBV‑specific binding antibody responses. stocktitan.net
- 3The Phase 2/3 Tumaini study will use a randomized, blinded, active‑controlled adaptive platform with a ring‑vaccination approach. stocktitan.net
- 4CEPI has committed up to US$58.5 million to support pre‑clinical work, Phase 1 trials in Canada and Uganda, and manufacturing of additional doses for the Tumaini study. finance.yahoo.com
- 5The trial is co‑sponsored by the Institut National de Recherche Biomédicale and the University of Antwerp, under the oversight of the DRC Ministry of Health. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.